Immuneering Corporation (IMRX)

Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $397.14 million. The enterprise value is $372.89 million.

Market Cap	397.14M
Enterprise Value	372.89M

Important Dates

The next estimated earnings date is Monday, November 10, 2025, after market close.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Immuneering has 63.24 million shares outstanding. The number of shares has increased by 12.61% in one year.

Current Share Class	63.24M
Shares Outstanding	63.24M
Shares Change (YoY)	+12.61%
Shares Change (QoQ)	+1.28%
Owned by Insiders (%)	13.98%
Owned by Institutions (%)	20.07%
Float	46.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	7.77
P/TBV Ratio	18.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.14.

Current Ratio	3.70
Quick Ratio	3.52
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -130.47% and return on invested capital (ROIC) is -77.34%.

Return on Equity (ROE)	-130.47%
Return on Assets (ROA)	-68.37%
Return on Invested Capital (ROIC)	-77.34%
Return on Capital Employed (ROCE)	-196.73%
Revenue Per Employee	n/a
Profits Per Employee	-$941,346
Employee Count	66
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +217.17% in the last 52 weeks. The beta is 0.47, so Immuneering's price volatility has been lower than the market average.

Beta (5Y)	0.47
52-Week Price Change	+217.17%
50-Day Moving Average	6.61
200-Day Moving Average	3.32
Relative Strength Index (RSI)	50.45
Average Volume (20 Days)	1,457,333

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-64.07M
Pretax Income	-62.13M
Net Income	-62.13M
EBITDA	-63.70M
EBIT	-64.07M
Earnings Per Share (EPS)	-$1.88

Balance Sheet

The company has $26.36 million in cash and $4.00 million in debt, giving a net cash position of $22.35 million or $0.35 per share.

Cash & Cash Equivalents	26.36M
Total Debt	4.00M
Net Cash	22.35M
Net Cash Per Share	$0.35
Equity (Book Value)	28.94M
Book Value Per Share	0.80
Working Capital	20.24M

Cash Flow

In the last 12 months, operating cash flow was -$51.51 million and capital expenditures -$25,685, giving a free cash flow of -$51.53 million.

Operating Cash Flow	-51.51M
Capital Expenditures	-25,685
Free Cash Flow	-51.53M
FCF Per Share	-$0.81

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.61%
Shareholder Yield	-12.61%
Earnings Yield	-15.72%
FCF Yield	-13.04%

Analyst Forecast

The average price target for Immuneering is $17.75, which is 182.64% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.75
Price Target Difference	182.64%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-20.60%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1